Researchers repurpose drug to deny drug-resistant fungus of iron, an element crucial to its survival
How do you fight a fungal infection that is becoming increasingly resistant to medicine? By starving it, found a team of University at Buffalo and Temple University researchers.
To treat Candida albicans, a common yeast that can cause illness in those with weakened immune systems, researchers limited the fungus’ access to iron, an element crucial to the organism’s survival.
“In the absence of novel drug candidates, drug repurposing aimed at using existing drugs to treat diseases is a promising strategy.”Mira Edgerton, research professor in the Department of Oral Biology at the UB School of Dental Medicine
They did so by using deferasirox, a medication used to treat blood disorders. Tested in mice, the results were promising: investigators decreased iron levels in saliva by four times, which altered the expression of more than 100 genes by the fungus, diminished its ability to infect oral mucosal tissue and caused a two-fold reduction in the organism’s survival rate.
“In the absence of novel drug candidates, drug repurposing aimed at using existing drugs to treat diseases is a promising strategy,” says Mira Edgerton, DDS, PhD, co-lead investigator of the study and research professor in the Department of Oral Biology at the UB School of Dental Medicine.
Edgerton, along with Sumant Puri, PhD, co-lead investigator and assistant professor in the Kornberg School of Dentistry at Temple University, published the study in March in Antimicrobial Agents and Chemotherapy.
Currently, only three major classes of clinical antifungal drugs exist. However, fungal drug resistance has steadily increased and no new classes of antifungals have emerged in decades, says Edgerton.
Candida albicans, a fungus among the group building resistance, is the agent behind a number of infections. They include oral thrush, a yeast infection in the mouth identified by a white film that coats the tongue and throat, causing painful swallowing; and denture-related stomatitis, a fungal infection that affects nearly two-thirds of U.S. denture wearers that causes inflammation, redness and swelling in the mouth.
The yeast is also the fourth leading cause of hospital-acquired bloodstream infections, which often have high mortality rates, says Edgerton.
Candida albicans is the most abundant fungus in the oral microbiome and relies heavily on saliva as a source for essential elements. Iron, the second most abundant metal in saliva, is a critical nutrient used by the fungus in several cellular processes, including energy production and DNA repair.
In mice, the group added deferasirox to drinking water to lower iron levels in saliva and reduce the availability of iron needed to sustain an infection.
The investigators found that Candida albicans in the mice who received the treatment were less likely to survive attacks by the immune system, subsisting at a 12 percent survival rate compared to a 25 percent survival rate in mice who did not receive the treatment.
The therapy also altered the expression of 106 genes by the fungus, a quarter of which were involved in the regulation of iron metabolism, directly regulated by iron or had iron-related functions. The study is the first report of iron starvation affecting gene expression of Candida albicans in real time during live infection, says Puri.
Other research has shown that treatment with deferasirox does not result in iron deficiency in adults with normal iron levels, forming the potential for preventative treatment for those who are also vulnerable to mucosal infections, says Puri.
The Latest on: Drug-resistant fungal infections
via Google News
The Latest on: Drug-resistant fungal infections
- Anti-microbial/Anti-fungal Tests Market Progression Status, Revenue Expectation to 2027on May 5, 2021 at 6:45 am
Microbial and fungal infections are a major cause of death globally and can even cause potential epidemics, creating a huge economic burden on countries, especially developing ones. To nip the spread ...
- Pfizer Acquires Biotech Company Developing Antifungal Treatmenton April 30, 2021 at 7:23 am
San Diego-based biotech company Amplyx Pharmaceuticals has been developing a drug to treat invasive fungal infections.
- NYU Langone, Catholic Health nab top safety grades in Leapfrog reporton April 30, 2021 at 2:30 am
Hospitals in the NYU Langone and Catholic Health systems were the only city sites to receive an A grade in the latest safety report from Leapfrog Group, a Washington, D.C.–based watchdog organization ...
- Pfizer buys Amplyx to expand drug-resistant treatment portfolioon April 28, 2021 at 3:59 pm
Pfizer Inc on Wednesday said it has acquired privately-held Amplyx Pharmaceuticals, which is developing a new treatment for drug-resistant ...
- Pfizer buys Amplyx to expand drug-resistant treatment portfolioon April 28, 2021 at 4:11 am
Pfizer Inc on Wednesday said it has acquired privately-held Amplyx Pharmaceuticals, which is developing a new treatment for drug-resistant "superbug" fungal infections in patients with compromised ...
- Pfizer buys Amplyx to expand drug-resistant treatment portfolioon April 28, 2021 at 3:56 am
CHICAGO (Reuters) – Pfizer Inc on Wednesday said it has acquired privately-held Amplyx Pharmaceuticals, which is developing a new treatment for drug-resistant “superbug” fungal infections in ...
- Pfizer buys Amplyx to expand drug-resistant treatment portfolioon April 28, 2021 at 3:46 am
which is developing a new treatment for drug-resistant "superbug" fungal infections in patients with compromised immune systems. If approved, Amplyx's lead drug fosmanogepix would be the first new ...
- Pfizer Acquires Amplyx Pharmaceuticalson April 28, 2021 at 3:45 am
Pfizer Inc. announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that ...
via Bing News